Supplier
Baptist Memorial Hospital-Booneville, INC.
Baptist Memorial Hospital-Booneville, INC. was paid $7.14M by Medicaid between Jan 2018 and Dec 2024, across 116 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoBAPTIST MEMORIAL HOSPITAL-BOONEVILLE, INC.
BOONEVILLE, MS 38829
BOONEVILLE, MS 38829
33aNPI1396709978assigned 04/12/2006
33bProvider typeNon-Pharmacy Dispensing Site
28Total paid$7.14M
24GClaims217,029
24DCodes billed116
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Non-Pharmacy Dispensing Site providers in Mississippi
Rank by total paid#1 of 5
Median peer was paid$282K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,007 | $1.07M | |
| 2019 | 28,906 | $1.06M | |
| 2020 | 21,875 | $747K | |
| 2021 | 30,619 | $962K | |
| 2022 | 40,028 | $1.12M | |
| 2023 | 36,890 | $1.20M | |
| 2024incomplete | 24,704 | $974K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 10,686 | 8,765 | $1.58M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 12,960 | 10,673 | $1.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,289 | 4,321 | $784K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 5,254 | 4,429 | $361K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.9% | 5,212 | 4,160 | $348K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.1% | 8,536 | 6,752 | $292K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 1,485 | 1,266 | $210K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 5,498 | 4,427 | $159K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 11,376 | 4,739 | $131K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.6% | 4,070 | 3,240 | $115K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 2,157 | 1,771 | $113K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 14,659 | 11,140 | $112K |
104 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,004 | $110K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,109 | $96K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 1,328 | $88K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 2,102 | $87K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 2,426 | $79K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 4,002 | $75K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,837 | $71K |
| 80053 | Comprehensive metabolic panel | <1% | 10,919 | $68K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,308 | $67K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,438 | $63K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,664 | $63K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,511 | $53K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,250 | $42K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 346 | $41K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 945 | $38K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 824 | $36K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,458 | $32K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,195 | $31K |
| 84484 | <1% | 4,627 | $26K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 121 | $24K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,198 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,747 | $19K |
| 81025 | <1% | 2,188 | $18K | |
| 83880 | <1% | 874 | $16K | |
| 81003 | <1% | 7,799 | $14K | |
| 83735 | <1% | 3,403 | $14K | |
| 71250 | <1% | 418 | $13K | |
| 87040 | <1% | 2,289 | $12K | |
| 83605 | <1% | 1,993 | $11K | |
| 94375 | <1% | 553 | $11K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,235 | $11K |
| 83690 | <1% | 2,704 | $11K | |
| 87807 | <1% | 798 | $8K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 230 | $8K |
| 85027 | <1% | 2,291 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 103 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,270 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 791 | $5K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 63 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 20 | $4K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 66 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 54 | $4K |
| 73630 | <1% | 83 | $4K | |
| 82803 | <1% | 262 | $4K | |
| 73610 | <1% | 67 | $3K | |
| 36600 | <1% | 133 | $3K | |
| 73560 | <1% | 82 | $2K | |
| 85007 | <1% | 1,324 | $2K | |
| 73130 | <1% | 48 | $2K | |
| 73030 | <1% | 65 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 46 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 21 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 19 | $1K |
| 73110 | <1% | 26 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 18 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 45 | $987.33 |
| 86140 | <1% | 269 | $805.80 | |
| 97162 | <1% | 27 | $804.62 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 93 | $751.41 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 21 | $611.80 |
| 74018 | <1% | 14 | $568.27 | |
| 93971 | <1% | 14 | $519.64 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 56 | $496.30 |
| 82150 | <1% | 108 | $450.80 | |
| 85610 | <1% | 215 | $393.02 | |
| 81001 | <1% | 270 | $376.74 | |
| 85379 | <1% | 76 | $358.39 | |
| 0012A | <1% | 13 | $322.22 | |
| 0011A | <1% | 12 | $246.82 | |
| 73502 | <1% | 14 | $200.98 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,581 | $196.02 |
| 84703 | <1% | 31 | $154.25 | |
| 87070 | <1% | 18 | $90.14 | |
| 80076 | <1% | 13 | $73.50 | |
| 80061 | Lipid panel | <1% | 14 | $72.54 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,931 | $69.80 |
| 82565 | <1% | 28 | $60.98 | |
| 87205 | <1% | 18 | $46.09 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,173 | $41.62 |
| A9270 | Non-covered item or service | <1% | 2,513 | $32.94 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 183 | $27.44 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 882 | $21.70 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,627 | $18.06 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 45 | $13.78 |
| 96376 | <1% | 135 | $8.29 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,370 | $5.75 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,794 | $4.83 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 182 | $3.96 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 389 | $2.19 |
| 90715 | <1% | 31 | $1.78 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,364 | $0.96 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 73 | $0.62 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 778 | $0.20 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 632 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 12 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 45 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 338 | $0.00 |
| 84145 | 0% | 143 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 831 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 379 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 112 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 141 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 80 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/ CLO)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.